Lay Summary
Predicting PSC with a Multi-Biomarker Model
New multi-biomarker blood test model predicts transplant-free survival with high accuracy in PSC.
Read MoreAcute Cholangitis Survey Update
A global survey reveals how acute cholangitis symptom patterns directly predict recovery times.
Read MoreA pilot study reveals blocking the IL-17 pathway is safe and feasible for primary sclerosing cholangitis
A pilot study reveals blocking the IL-17 pathway is safe and feasible for primary sclerosing cholangitis.
Read MoreVolixibat Announcement at EASL Congress 2026
The latest results from the VISTAS trial to reduce itch in PSC.
Read MoreVISTAS Phase 2b Trial Results May 2026
New trial data shows volixibat significantly reduces severe itch for people with PSC.
Read MoreSABR-PSC Clinical Trial Results
Early-phase study shows brodalumab is safe and well-tolerated in people with PSC.
Read MoreRitivixibat (A3907) Phase 2 Clinical Trial Results
Safety results for the Phase 2 ritivixibat study (A3907) for PSC have been released.
Read MorePiSCATIN study reaches full recruitment milestone
The PiSCATIN study has enrolled 570 participants, moving us closer to potential PSC treatments.
Read MoreFebruary 2026 Research Roundup
A month of leadership growth, breakthrough research, and new milestones in clinical care.
Read MoreDriving Global Change Through the Patient Voice
New global survey results reveal the significant impact of itch on life with PSC.
Read More